Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Niall Martin
|
| gptkbp:collaboratedWith |
gptkb:Novartis
gptkb:Merck_KGaA |
| gptkbp:focusesOn |
DNA damage response (DDR) therapeutics
|
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
Niall Martin
|
| gptkbp:fundedBy |
gptkb:IP_Group
gptkb:M_Ventures gptkb:SV_Health_Investors Andera Partners Arix Bioscience Life Science Partners |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Artios Pharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:specializesIn |
gptkb:cancer
|
| gptkbp:website |
https://www.artiospharma.com/
|
| gptkbp:bfsParent |
gptkb:SR_One
gptkb:SV_Health_Investors |
| gptkbp:bfsLayer |
8
|